HomeNDC LookupIngredientsPhenylephrine Hydrochloride › 71872-7267-01
Phenylephrine Hydrochloride 10 mg/mL Injection, 1 vial — NDC 71872-7267-01 package photo

Phenylephrine Hydrochloride 10 mg/mL Injection, 1 vial

by Medical Purchasing Solutions, LLC · 1 VIAL, SINGLE-DOSE in 1 BAG (71872-7267-1) / 1 mL in 1 VIAL, SINGLE-DOSE
NDC 71872-7267-01
🏷️ FDA NDC (as labeled) 71872-7267-1 billing pads the package segment with a zero
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

🆔 Identity & classification

FDA NDC (as labeled) 71872-7267-1
Product NDC 71872-7267
11-digit billing NDC 71872726701
RxCUI 1666372
UNII 04JA59TNSJ
UPC 0355150300013
Application # ANDA210696
SPL Set ID d1639934-8aa6-2364-e053-2995a90a9923
Established class (EPC) alpha-1 Adrenergic Agonist
Mechanism of action Adrenergic alpha1-Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2021-01-07
Route INTRAVENOUS
Dosage form INJECTION
Substance PHENYLEPHRINE HYDROCHLORIDE
TE code (Orange Book) AP2 · RLD · RS
Why two NDCs? The FDA registers this code as 71872-7267-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 71872-7267-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the alpha-1 Adrenergic Agonist class.

Pharmacologic class alpha-1 Adrenergic Agonist
Drug family (ATC) Sympathomimetics excl. antiglaucoma preparations, Adrenergic and dopaminergic agents, Other agents for treatment of hemorrhoids and anal fissures for topical use
How it works Adrenergic alpha1-Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerMedical Purchasing Solutions, LLC
Application holderEUGIA PHARMA SPECIALITIES LTD
FDA applicationANDA210696 (ANDA)
Labeler code71872
First marketedJan 2021
Product typeHuman Prescription Drug
Portfolio250 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

📗 Our plain-language guide HelloPharmacist
  • Yes, it's the same active ingredient, but used in very different ways depending on the form. The nasal spray delivers a tiny amount directly to the nasal lining to temporarily shri...
  • I see phenylephrine in nasal sprays at the pharmacy AND as an IV drug in the hospital — is it really the same medication?
  • You should check with your doctor first. Phenylephrine constricts blood vessels, which can raise blood pressure and put extra strain on the heart — even from a nasal spray. If you...
  • Can I use the nasal spray if I have high blood pressure or heart disease?
📖 Read our full Phenylephrine guide →

Supplement & herbal interactions

Some supplements/herbs that may interact with Phenylephrine Hydrochloride — tap one for details:

Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • 1 mg / 1 mL UNII 2968PHW8QP
    A weak organic acid derived from citrus fruits or made through fermentation. It works as a buffer to control pH, a preservative to extend shelf life, and a flavoring agent in medications.
  • UNII QTT17582CB
    A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
  • 3.5 mg / 1 mL UNII 451W47IQ8X
    Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
  • 2 mg / 1 mL UNII 4VON5FNS3C
    Sodium metabisulfite is a preservative derived from sulfur compounds. It prevents microbial growth and oxidation in medicines, helping extend shelf life and maintain product stability.
  • 4 mg / 1 mL UNII B22547B95K
    A salt derived from citric acid that helps maintain the proper acid-base balance in the medicine. It's used as a buffer to keep the product stable and at the right pH level.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

7 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Phenylephrine Hydrochloride 10 mg/mL 00404-9931-99 Henry 1 vial AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 00641-6142-25 Hikma 25 vials FDA listed
Phenylephrine Hydrochloride 10 mg/mL 00641-6229-25 Hikma 25 vials FDA listed
Phenylephrine Hydrochloride 10 mg/mL 00781-3422-92 Sandoz 10 vials AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 00781-9226-92 Sandoz 10 vials AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 14335-0440-01 Hainan 25 vials AP1 FDA listed
phenylephrine hydrochloride 10 mg/mL 23155-0620-41 Heritage 25 vials AP2 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 25021-0315-01 Sagent 25 vials AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 31722-0343-32 Camber 10 vials AP1 FDA listed
phenylephrine hydrochloride 10 mg/mL 36000-0358-25 Baxter 25 vials AP1 FDA listed
Biorphen 10 mg/mL 43598-0199-10 Dr. 10 ampules AP FDA listed
Phenylephrine Hci 10 mg/mL 51662-1249-01 HF 1 ml FDA listed
Phenylephrine Hydrochloride 10 mg/mL 51662-1576-01 HF 1 ml AP2 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 55150-0300-25 Eugia 25 vials AP2 FDA listed
Phenylephrine hydrochloride 10 mg/mL 55154-8226-05 Cardinal 5 vials AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 58657-0851-26 Method 25 vials AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 63323-0751-13 Fresenius 25 vials AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 65145-0115-25 Caplin 25 vials AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 65219-0388-01 Fresenius 25 vials AP2 FDA listed
Phenylephrine Hydrochloride Phenylephrine Hydrochloride 10 mg/mL 68083-0465-25 Gland 25 vials AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 70069-0801-25 Somerset 25 vials AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 70069-0811-25 Somerset 25 vials AP1 FDA listed
Phenylephrine hydrochloride 10 mg/mL 70121-1577-05 Amneal 25 vials AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 70594-0063-02 Xellia 25 vials AP1 FDA listed
Phenylephrine hydrochloride 10 mg/mL 70756-0621-25 Lifestar 25 vials AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 71288-0807-02 Meitheal 25 vials AP2 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 71839-0127-25 BE 25 vials AP2 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 71872-7043-01 Medical 1 vial FDA listed
Phenylephrine hydrochloride 10 mg/mL 71872-7159-01 Medical 1 vial AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mLthis 71872-7267-01 Medical 1 vial AP2 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 71872-7273-01 Medical 1 vial AP1 FDA listed
Phenylephrine hydrochloride 10 mg/mL 71872-7303-01 Medical 1 vial AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 71872-7343-01 Medical 1 vial AP2 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 71872-7348-01 Medical 1 vial AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 72205-0264-25 Novadoz 25 vials AP2 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 72485-0504-25 Armas 25 vials AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 72572-0571-25 Civica, 25 vials FDA listed
Phenylephrine hydrochloride 10 mg/mL 81284-0211-25 Provepharm 25 vials AP1 FDA listed
Phenylephrine hydrochloride 10 mg/mL 84549-0621-25 ProPharma 1 ml AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 00781-9227-95 Sandoz 10 vials AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 00781-9228-70 Sandoz 1 vial AP1 FDA listed
phenylephrine hydrochloride 10 mg/mL 68083-0338-10 Gland 10 vials AP1 FDA listed
phenylephrine hydrochloride 10 mg/mL 68083-0339-01 Gland 1 vial AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 71288-0808-76 Meitheal 10 vials AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 55150-0301-10 Eugia 10 vials AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 55150-0302-01 Eugia 1 vial AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 71839-0128-10 BE 10 vials AP2 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 71839-0129-10 BE 10 vials AP2 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 31722-0344-31 Camber 10 vials AP1 FDA listed
phenylephrine hydrochloride 10 mg/mL 36000-0362-05 Baxter 5 vials AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 00641-6188-10 Hikma 10 vials FDA listed
Phenylephrine Hydrochloride 10 mg/mL 00781-3458-95 Sandoz 10 vials AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 72205-0265-07 Novadoz 10 vials AP2 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 14335-0442-01 Hainan 1 vial AP1 FDA listed
Phenylephrine hydrochloride 10 mg/mL 42023-0215-01 Par 1 vial FDA listed
Phenylephrine Hydrochloride 10 mg/mL 58657-0853-01 Method 10 ml AP1 FDA listed
Phenylephrine hydrochloride 10 mg/mL 70121-1578-07 Amneal 10 vials AP1 FDA listed
Phenylephrine hydrochloride 10 mg/mL 70121-1579-01 Amneal 1 vial AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 58657-0852-11 Method 10 vials AP1 FDA listed
phenylephrine hydrochloride 10 mg/mL 36000-0360-10 Baxter 10 vials AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 00781-3466-70 Sandoz 1 vial AP1 FDA listed
Phenylephrine hydrochloride 10 mg/mL 42023-0214-10 Par 10 vials FDA listed
Phenylephrine Hydrochloride 10 mg/mL 72205-0266-07 Novadoz 10 vials AP2 FDA listed
Phenylephrine hydrochloride 10 mg/mL 81284-0212-10 Provepharm 10 vials AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 31722-0345-10 Camber 1 vial AP1 FDA listed
Phenylephrine hydrochloride 10 mg/mL 81284-0213-01 Provepharm 1 vial AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 00641-6189-10 Hikma 10 vials FDA listed
Phenylephrine Hydrochloride 10 mg/mL 14335-0441-01 Hainan 10 vials AP1 FDA listed
Phenylephrine Hydrochloride 10 mg/mL 72572-0570-10 Civica, 10 vials FDA listed
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2021
On the market since
Jan 2021
📍
2026
Currently FDA-listed
5 years listed
🔓
·
Generic on the market
this product is a generic
This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
71872-7267-01 You're viewing this 1 VIAL, SINGLE-DOSE in 1 BAG (71872-7267-1) / 1 mL in 1 VIAL, SINGLE-DOSE 2021-09-20 Active

🧭 About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The FDA registers it as 71872-7267-1, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 71872-7267-01, written without dashes as 71872726701. The Identity section at the top of this page lists every form of this code.
What do the three segments of this NDC mean?
In 71872-7267-01, the first segment (71872) is the labeler code FDA assigned to Medical Purchasing Solutions, LLC; the middle segment (7267) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (01) identifies this exact package size and type. Together they name one specific package of one specific product.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Medical Purchasing Solutions, LLC. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Medical Purchasing Solutions, LLC is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 71 words

1 INDICATIONS AND USAGE Phenylephrine hydrochloride injection is an alpha-1 adrenergic receptor agonist indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation, in such settings as septic shock or anesthesia. Phenylephrine hydrochloride injection is an alpha-1 adrenergic receptor agonist indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation, in such settings as septic shock or anesthesia.

( 1 )

⏱️ Dosage and Administration ~2 min read

2 DOSAGE AND ADMINISTRATION Dilute before administration. ( 2.1 ) Dosing for Perioperative Hypotension Intravenous bolus administration: 50 mcg to 250 mcg ( 2.4 ) Intravenous continuous infusion: 0.5 mcg/kg/minute to 1.4 mcg/kg/minute titrated to effect ( 2.4 ) Dosing for Patients with Vasodilatory Shock Intravenous continuous infusion: 0.5 mcg/kg/minute to 6 mcg/kg/minute titrated to effect ( 2.5 )

2.1General Administration Instructions Phenylephrine hydrochloride injection must be diluted before administration as bolus intravenous infusion or continuous intravenous infusion. Inspect the solution for particulate matter and discoloration prior to administration. The diluted solution should not be held for more than 4 hours at room temperature or for more than 24 hours under refrigerated conditions.

Discard any unused portion. During phenylephrine hydrochloride injection administration: Correct intravascular volume depletion. Correct acidosis.

Acidosis may reduce the effectiveness of phenylephrine.

2.2Preparing a 100 mcg/mL Solution for Bolus Intravenous Administration For bolus intravenous administration, withdraw 10 mg (1 mL of a 10 mg/mL concentration) of phenylephrine hydrochloride injection and dilute with 99 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP. This will yield a final concentration of 100 mcg/mL. Withdraw an appropriate dose from the 100 mcg/mL solution prior to bolus intravenous administration.

2.3Preparing a Solution for Continuous Intravenous Infusion For continuous intravenous infusion, withdraw 10 mg (1 mL of 10 mg/mL concentration) of phenylephrine hydrochloride injection and add to 500 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP (providing a final concentration of 20 mcg/mL).

2.4Dosing for Perioperative Setting In adult patients undergoing surgical procedures with either neuraxial anesthesia or general anesthesia: 50 mcg to 250 mcg by intravenous bolus administration. The most frequently reported initial bolus dose is 50 mcg or 100 mcg. 0.5 mcg/kg/min to 1.4 mcg/kg/min by intravenous continuous infusion, titrated to blood pressure goal.

2.5Dosing for Septic or Other Vasodilatory Shock In adult patients with septic or other vasodilatory shock: No bolus. 0.5 mcg/kg/min to 6 mcg/kg/min by intravenous continuous infusion, titrated to blood pressure goal. Doses above 6 mcg/kg/min do not show significant incremental increase in blood pressure.

💊 Dosage Forms and Strengths 44 words

3 DOSAGE FORMS AND STRENGTHS Injection: 10 mg/mL phenylephrine hydrochloride injection, USP is supplied as a 1 mL single-dose vial (10 mg of phenylephrine hydrochloride per vial). Injection: 10 mg/mL supplied as a 1 mL single-dose vial ( 3 , 11 , 16 )

Contraindications 32 words

4 CONTRAINDICATIONS The use of phenylephrine hydrochloride injection is contraindicated in patients with: Hypersensitivity to it or any of its components Hypersensitivity to it or any of its components ( 4 )

⚠️ Warnings and Cautions ~1 min read

5 WARNINGS AND PRECAUTIONS Severe bradycardia and decreased cardiac output ( 5.2 ) Extravasation : during intravenous administration may cause necrosis or sloughing of tissue ( 5.4 ) Concomitant use with oxytocic drugs : pressor effect of sympathomimetic pressor amines is potentiated ( 5.5 ) Allergic-type reactions : Sulfite ( 5.6 )

5.1Exacerbation of Angina, Heart Failure, or Pulmonary Arterial Hypertension Because of its pressor effects, phenylephrine hydrochloride can precipitate angina in patients with severe arteriosclerosis or history of angina, exacerbate underlying heart failure, and increase pulmonary arterial pressure.

5.2Bradycardia Phenylephrine hydrochloride can cause severe bradycardia and decreased cardiac output.

5.3Risk in Patients with Autonomic Dysfunction The pressor response to adrenergic drugs, including phenylephrine, can be increased in patients with autonomic dysfunction, as may occur with spinal cord injuries.

5.4Skin and Subcutaneous Necrosis Extravasation of phenylephrine can cause necrosis or sloughing of tissue.

5.5Pressor Effect with Concomitant Oxytocic Drugs Oxytocic drugs potentiate the pressor effect of sympathomimetic pressor amines including phenylephrine hydrochloride [see Drug Interactions (7.1) ] , with the potential for hemorrhagic stroke.

5.6Allergic Reactions This product contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

5.7Peripheral and Visceral Ischemia Phenylephrine hydrochloride can cause excessive peripheral and visceral vasoconstriction and ischemia to vital organs, particularly in patients with extensive peripheral vascular disease.

5.8Renal Toxicity Phenylephrine hydrochloride can increase the need for renal replacement therapy in patients with septic shock. Monitor renal function.

🤒 Adverse Reactions 138 words

6 ADVERSE REACTIONS The following adverse reactions associated with the use of phenylephrine hydrochloride were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure. Cardiac disorders: Bradycardia, AV block, ventricular extrasystoles, myocardial ischemia Gastrointestinal disorders: Nausea, vomiting General disorders and administrative site conditions: Chest pain, extravasation Immune system disorders: Sulfite sensitivity Nervous system disorders: Headache, nervousness, paresthesia, tremor Psychiatric disorders: Excitability Respiratory: Pulmonary edema, rales Skin and subcutaneous tissue disorders: Diaphoresis, pallor, piloerection, skin blanching, skin necrosis with extravasation Vascular disorders: Hypertensive crisis Most common adverse reactions: nausea and vomiting, headache, nervousness ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact AuroMedics Pharma LLC at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🔄 Drug Interactions 117 words

7 DRUG INTERACTIONS Agonistic effects with monoamine oxidase inhibitors (MAOI), β-adrenergic blocking agents, α-2 adrenergic agonists, steroids, tricyclic antidepressants, norepinephrine transport inhibitors, ergot alkaloids, centrally-acting sympatholytic agents and atropine sulfate ( 7.1 ) Antagonistic effects on and by α-adrenergic blocking agents ( 7.2 )

7.1Agonists The pressor effect of phenylephrine hydrochloride is increased in patients receiving: Monoamine oxidase inhibitors (MAOI), such as selegiline. β-adrenergic blockers α-2 adrenergic agonists, such as clonidine Steroids Tricyclic antidepressants Norepinephrine transport inhibitors, such as atomoxetine Ergot alkaloids, such as methylergonovine maleate Centrally-acting sympatholytic agents, such as guanfacine or reserpine Atropine sulfate

7.2Antagonists α-adrenergic blocking agents, including phenothiazines (e.g., chlorpromazine) and amiodarone block phenylephrine and are in turn blocked by phenylephrine.

👥 Use in Specific Populations ~1 min read

8 USE IN SPECIFIC POPULATIONS

8.1Pregnancy Pregnancy Category C Animal reproduction studies have not been conducted with intravenous phenylephrine. It is also not known whether phenylephrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Phenylephrine hydrochloride should be given to a pregnant woman only if clearly needed.

8.2Labor and Delivery The most common maternal adverse reactions reported in studies of phenylephrine use during neuraxial anesthesia during cesarean delivery include nausea and vomiting, which are commonly associated with hypotension, bradycardia, reactive hypertension, and transient arrhythmias. Phenylephrine does not appear to cause a decrease in placental perfusion sufficient to alter either the neonate Apgar scores or blood-gas status.

8.3Nursing Mothers It is not known whether this drug is excreted in human milk.

8.4Pediatric Use Safety and effectiveness in pediatric patients have not been established.

8.5Geriatric Use Clinical studies of phenylephrine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

8.6Hepatic Impairment In patients with liver cirrhosis [Child Pugh Class A (n = 3), Class B (n = 5) and Class C (n = 1)], dose-response data indicate decreased responsiveness to phenylephrine. Consider using larger doses than usual in hepatic impaired subjects.

8.7Renal Impairment In patients with end stage renal disease (ESRD) undergoing hemodialysis, dose-response data indicates increased responsiveness to phenylephrine. Consider using lower doses of phenylephrine hydrochloride in ESRD patients.

🤰 Pregnancy 50 words

8.1Pregnancy Pregnancy Category C Animal reproduction studies have not been conducted with intravenous phenylephrine. It is also not known whether phenylephrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Phenylephrine hydrochloride should be given to a pregnant woman only if clearly needed.

🧒 Pediatric Use 13 words

8.4Pediatric Use Safety and effectiveness in pediatric patients have not been established.

🧓 Geriatric Use 83 words

8.5Geriatric Use Clinical studies of phenylephrine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

🆘 Overdosage 52 words

10 OVERDOSAGE Overdose of phenylephrine hydrochloride can cause a rapid rise in blood pressure. Symptoms of overdose include headache, vomiting, hypertension, reflex bradycardia, and cardiac arrhythmias including ventricular extrasystoles and ventricular tachycardia, and may cause a sensation of fullness in the head and tingling of the extremities. Consider using an α-adrenergic antagonist.

🧬 Clinical Pharmacology 216 words

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action Phenylephrine hydrochloride is an α-1 adrenergic receptor agonist.

12.2Pharmacodynamics Phenylephrine is the active moiety. Metabolites are inactive at both the α-1 and α-2 adrenergic receptors. Following parenteral administration of phenylephrine hydrochloride, increases in systolic blood pressure, diastolic blood pressure, mean arterial blood pressure, and total peripheral vascular resistance are observed.

The onset of blood pressure increase following an intravenous bolus phenylephrine hydrochloride administration is rapid and the effect may persist for up to 20 minutes. As mean arterial pressure increases following parenteral doses, vagal activity also increases, resulting in reflex bradycardia. Most vascular beds are constricted, including renal, splanchnic, and hepatic.

12.3Pharmacokinetics Following an intravenous infusion of phenylephrine hydrochloride, the effective half-life was approximately 5 minutes. The steady-state volume of distribution (340 L) exceeded the body volume by a factor of 5, suggesting a high distribution into certain organ compartments. The average total serum clearance (2095 mL/min) was close to one-third of the cardiac output.

A mass balance study showed that phenylephrine is extensively metabolized by the liver with only 12% of the dose excreted unchanged in the urine. Deamination by monoamino oxidase is the primary metabolic pathway resulting in the formation of the major metabolite (m-hydroxymandelic acid) which accounts for 57% of the total administered dose.

🧬 Mechanism of Action 12 words

12.1Mechanism of Action Phenylephrine hydrochloride is an α-1 adrenergic receptor agonist.

📦 How Supplied / Storage and Handling 101 words

16 HOW SUPPLIED/STORAGE AND HANDLING Phenylephrine hydrochloride injection, USP is a clear, colorless, aqueous solution and is supplied as follows: 10 mg per mL: 1 mL Single-Dose Vials packaged in a carton of 25 NDC 55150-300-25 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light. Keep covered in carton until time of use.

For single-dose only. The diluted solution should not be held for more than 4 hours at room temperature or for more than 24 hours under refrigerated conditions. Discard any unused portion.

The vial stoppers are not made with natural rubber latex.

📋 Description 136 words

11 DESCRIPTION Phenylephrine hydrochloride is a synthetic sympathomimetic agent in sterile form for parenteral injection. Chemically, phenylephrine hydrochloride is (-)- m -Hydroxy-α-[(methylamino)methyl]benzyl alcohol hydrochloride and has the following structural formula: Phenylephrine hydrochloride USP is white or practically white powder. Phenylephrine hydrochloride is very soluble in water, freely soluble in ethanol, and insoluble in chloroform and ethyl ether.

Phenylephrine hydrochloride is sensitive to light. Phenylephrine hydrochloride injection, USP is a clear, colorless, aqueous solution that is essentially free of visible foreign matter. Each mL contains: Phenylephrine Hydrochloride USP, 10 mg; Sodium Chloride 3.5 mg; Sodium Citrate Dihydrate 4 mg; Citric Acid Monohydrate 1 mg; and Sodium Metabisulfite 2 mg in water for injection.

The pH may be adjusted in the range of 3.5 to 5.5 with Sodium Hydroxide and/or Hydrochloric Acid, if necessary. Phenylephrine Hydrochloride Chemical Structure

💬 Information for Patients 123 words

17 PATIENT COUNSELING INFORMATION Inform patients, families, or caregivers that the primary side effect of phenylephrine is hypertension and rarely, hypertensive crisis. Patients may experience bradycardia (slow heart rate), which in some cases may produce heart block or other cardiac arrhythmias, extra ventricular beats, myocardial ischemia in patients with underlying cardiac disease, and pulmonary edema (fluid in the lungs) or rales. Common, less serious symptoms include the following: chest pain skin or tissue damage if the drug leaks out of the venous catheter into the surrounding tissue headache, nervousness, tremor, numbness/tingling (paresthesias) in hands or feet nausea, vomiting excitability, dizziness, sweating, flushing Distributed by: AuroMedics Pharma LLC 279 Princeton-Hightstown Rd.

E. Windsor, NJ 08520 Manufactured by: Aurobindo Pharma Limited Hyderabad - 500038 India

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.